This small-cap stock surged 75% since IPO price but ICICI Securities sets target below CMP; what should shareholders do?
ICICI Bank secured new business in an ipo & listings development.
· LiveMint Markets
Sudeep Pharma shares have climbed nearly 75% above their IPO price, but ICICI Securities says expectations for its emerging battery materials business are already reflected in the valuation. The brokerage retained its Hold rating while raising its target price to ₹1,000.
The analysis
ICICI Bank reported ₹1,000, with movement of 75% attached to those lines. Those are the figures as filed — what moves the price is how they sit against what the market already expected, not their absolute size.
Against that, the stock is -1.3% on the day at ₹1,342.00, and has returned -4.5% over three months. It sits 8% below its 52-week high. The banks sector has moved -2.1% over the same period, so ICICI Bank is running 2.4 points behind its peers.
For ICICI Bank, the question is how much of this is already reflected in the price and how much re-rates the banks peer set alongside it.
Why it matters
- Listing activity is a read on risk appetite — a hot primary market usually means a confident secondary one.
- The shift to renewables is redrawing which energy names are structural winners versus stranded.
Market context
- The company directly in focus is ICICIBANK.
- Sector exposure: Banks, Pharma & Healthcare.
- The immediate tone of coverage reads positive.
In this story
Related coverage
Zetwerk, Bonfiglioli Transmissions, Tonbo, SMT announce IPO price bands
Despite ICICI Life’s good Q2, investors must watch these risks
ICICI Prudential Life Insurance to focus on growing absolute VNB amid slump in FY24
ICICI Pru Life Q4 net profit falls 26% to Rs 174 cr, insurer announces dividend
Gujarat State Petronet falls sharply from day#39;s high as tariff cut triggers flurry of downgrades